Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pralsetinib - Blueprint Medicines

Next Previous
Drug Profile

Pralsetinib - Blueprint Medicines

Alternative Names: BLU-667; CS 3009; GAVRETO; Gavreto; Phukiva®; Praltinib; Pratinib; Prucifina®; Prudential®; Pujihua; RG 6396

Latest Information Update: 03 Aug 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Blueprint Medicines
  • Developer Blueprint Medicines; CStone Pharmaceuticals; Rigel Pharmaceuticals; Roche
  • Class Amides; Amines; Antineoplastics; Cyclohexanes; Ethers; Fluorinated hydrocarbons; Pyrazoles; Pyridines; Pyrimidines; Small molecules
  • Mechanism of Action Proto-oncogene protein c-ret inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Thyroid cancer; Non-small cell lung cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Non-small cell lung cancer; Thyroid cancer
  • Phase I/II Solid tumours

Most Recent Events

  • 03 Aug 2026 Discontinued - Phase-I/II for Thyroid cancer (Late-stage disease, Inoperable/Unresectable, Second-line therapy or greater) in Singapore (PO)
  • 02 Jun 2026 Efficacy and adverse events data from a phase II TAPISTRY trial in Solid tumours presented at the 62nd Annual Meeting of the American Society of Clinical Oncology (ASCO-2026)
  • 02 Jun 2026 Updated efficacy and adverse events data from the phase I/II ARROW trial in Thyroid cancer presented at the 62nd Annual Meeting of the American Society of Clinical Oncology (ASCO-2026)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top